Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

4/19 Movers


ECOM +19% Reported preliminary revenue and EBITDA, above high range of guidance. Includes estimated net loss.

BPTH +16% Pretty easy fade, a nanocap bio that was coming down in the PM. The trial was a preclinical one, with mice. The results were for treatment of solid tumors. A month ago, this drug had results for a ph 2 trial of leukemia. So same drug for 2 different diseases? Sounds like BS. 

AAOI +12% Had come down a lot over the past few months. No apparent news for rally. A whopping 79% of the float is short.

SIEN +8% Up on FDA approval of breast implant supplement.

MYO +8% Up on no news.

CIFS +8% Continued uptrend despite Muddy Waters protests. 

CRSP +8% Continued 3 day uptrend off positive data on 4/16. 

ENPH +8% Roth ug to $6 from $5.50. Stock had been downtrending recently, did a 3 day uptrend.

TCBI +8% Beat estimates. 

ADMS +7% Announced final results from ph3 study of Gocovri. Drug has already been FDA approved.

VRAY +7% Up on news that ViewRay's Linac system is used for the first time by Amsterdam medical center.


ACET -64% Lots of pricing pressures against generics. Company breaking debt covenants. Decreasing revenues, likely a BK situation. Generics will continue to have pricing pressure.

SHOS -34% Down on big loss per share. Fell another 16% the next day.

HMNY -33% Down on huge $150M ATM, and another offering. Fell another 10% the next day.

PIR -21% Earnings guidance negative, when concensus was positive.

LLIT -17% Nanocap Chinese medical device company. Unpredictable, no news.

INNT -16%

PM -16%

PRTK -15%

SNBR -14%

DRRX -13%

IZEA -13%

ALRN -12%